Honglian Gui

机构：Shanghai Jiao Tong University, Ruijin Hospital, Anhui Provincial Hospital · ORCID：0000-0003-3624-4800

发表论文 40 篇 · 总被引 946 次 · h-index 17

代表论文

• VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 (2022 · New England Journal of Medicine · 被引 229)
• Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk (2018 · Expert Opinion on Biological Therapy · 被引 39)
• Letter to the editor: Exacerbation of autoimmune hepatitis after COVID‐19 vaccination (2021 · Hepatology · 被引 34)
• Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis (2020 · Journal of Clinical and Translational Hepatology · 被引 27)
• Laboratory-based Surveillance and Clinical Profile of Sporadic HEV Infection in Shanghai, China (2021 · Virologica Sinica · 被引 23)
• External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy (2021 · Frontiers in Medicine · 被引 21)